Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 4 | 5 |
| List of Tables | 6 | 1 |
| List of Figures | 6 | 3 |
| Introduction | 9 | 14 |
| Therapy Area Introduction | 9 | 1 |
| Symptoms | 10 | 1 |
| Gastroesophageal Reflux Disease | 10 | 1 |
| Irritable Bowel Syndrome | 10 | 1 |
| Inflammatory Bowel Disease | 10 | 1 |
| Etiology and Pathophysiology | 11 | 1 |
| Gastroesophageal Reflux Disease | 11 | 1 |
| Irritable Bowel Syndrome | 12 | 2 |
| Inflammatory Bowel Disease | 14 | 1 |
| Co-morbidities and Complications | 15 | 1 |
| Epidemiology Patterns and Forecasts Prevalence and Patient Segmentation | 16 | 1 |
| Gastroesophageal Reflux Disease | 17 | 1 |
| Irritable Bowel Syndrome | 17 | 1 |
| Inflammatory Bowel Disease | 18 | 1 |
| Treatment | 19 | 1 |
| Acid-Controlling Agents | 19 | 1 |
| Antacids | 19 | 1 |
| Histamine-2 Receptor Antagonist | 19 | 1 |
| Proton Pump Inhibitors | 19 | 1 |
| Anticholinergics/Antispasmodics | 20 | 1 |
| Gastric Stimulants, Laxatives and Antidiarrheals | 20 | 1 |
| Anti-inflammatory and Systemic Immunosuppressive Agents | 21 | 1 |
| Aminosalicylates | 21 | 1 |
| Immunomodulators | 21 | 1 |
| Corticosteroids | 21 | 1 |
| Biologics | 22 | 1 |
| Key Marketed Products | 23 | 22 |
| Overview | 23 | 1 |
| Humira (adalimumab) | 24 | 2 |
| Remicade (infliximab) | 26 | 2 |
| Soliris (eculizumab) | 28 | 1 |
| Tysabri (natalizumab) | 29 | 2 |
| Nexium (esomeprazole magnesium) | 31 | 2 |
| Entyvio (vedolizumab) | 33 | 2 |
| Protonix (pantoprazole) | 35 | 2 |
| Ocaliva (obeticholic acid) | 37 | 1 |
| Dexilant (dexlansoprazole) | 38 | 2 |
| Amitiza (lubiprostone) | 40 | 1 |
| Takecab (vonoprazan) | 41 | 2 |
| Linzess (linaclotide) | 43 | 2 |
| Pipeline Landscape Assessment | 45 | 27 |
| Overview | 45 | 2 |
| Molecule Types in the Pipeline | 47 | 1 |
| Molecular Targets in the Pipeline | 48 | 2 |
| Clinical Trials Landscape | 50 | 1 |
| Clinical Trial Failure Rates | 51 | 1 |
| Clinical Trial Failure Rates by Stage of Development | 51 | 1 |
| Clinical Trial Failure Rates by Indication | 51 | 1 |
| Clinical Trial Failure Rates by Molecule Type | 52 | 1 |
| Clinical Trial Failure Rates by Molecular Target | 53 | 1 |
| Clinical Trial Duration | 54 | 1 |
| Clinical Trial Duration by Stage of Development | 54 | 1 |
| Clinical Trial Duration by Indication and Stage of Development | 55 | 1 |
| Clinical Trial Duration by Molecule Type and Stage of Development | 56 | 1 |
| Clinical Trial Duration by Molecular Target and Stage of Development | 57 | 1 |
| Clinical Trial Size | 58 | 1 |
| Clinical Trial Size by Stage of Development | 58 | 1 |
| Clinical Trial Size by Indication and Stage of Development | 59 | 1 |
| Clinical Trial Size by Molecule Type and Stage of Development | 60 | 1 |
| Clinical Trial Size by Molecular Target and Stage of Development | 60 | 1 |
| Cumulative Clinical Trial Size | 61 | 1 |
| Indication, Molecule Type and Molecular Target | 62 | 2 |
| Late-Stage Drugs of the Developmental Pipeline | 64 | 1 |
| RPC1063 (ozanimod) Celgene | 64 | 1 |
| Drug Forecast | 65 | 1 |
| GED-0301 (mongersen) Celgene | 65 | 1 |
| Drug Forecast | 66 | 1 |
| Stelara (ustekinumab) Johnson &Johnson | 66 | 1 |
| Drug Forecast | 67 | 1 |
| Victoza (liraglutide) Novo Nordisk | 68 | 1 |
| Drug Forecast | 69 | 1 |
| Plecanatide Synergy Pharmaceuticals | 69 | 1 |
| Drug Forecast | 70 | 1 |
| Conclusion | 70 | 2 |
| Multi-scenario Market Forecast to 2022 | 72 | 8 |
| Overall Market Size | 72 | 2 |
| Generic Penetration | 74 | 1 |
| Revenue Forecast by Molecular Target | 75 | 1 |
| Tumor Necrosis Factor Alpha | 75 | 1 |
| Interleukins and Receptors | 76 | 1 |
| H+/K+ ATPase | 77 | 1 |
| Integrins | 78 | 2 |
| Company Analysis and Positioning | 80 | 19 |
| Revenue and Market Share Analysis by Company | 81 | 4 |
| AbbVie Will Patent Expiry of Humira Significantly Diminish Revenues? | 85 | 2 |
| Takeda Will Entyvio and Takecab be the Predominant Contributors to Revenue Growth? | 87 | 1 |
| Johnson &Johnson To What Extent Will Simponi Offset the Patent Expiry of Remicade? | 88 | 2 |
| AstraZeneca 0T 0TWill Patent Expiration of Blockbuster Drug and Lack of Strong Pipeline Line-up Result in Loss of Market Share? | 90 | 2 |
| Alexion Is Soliris Success Enough to Drive Strong Company Growth? | 92 | 1 |
| Allergan To What Extent Will Key Gastrointestinal Product Linzess Drive Company Growth? | 93 | 2 |
| Celgene Which Gastrointestinal Pipeline Drugs Will Drive Growth in Second Half of Forecast Period? | 95 | 1 |
| Company Landscape | 96 | 1 |
| Marketed and Pipeline Portfolio Analysis | 96 | 3 |
| Strategic Consolidations | 99 | 12 |
| Licensing Deals | 99 | 1 |
| Deals by Region, Year and Value | 99 | 2 |
| Deals by Stage of Development and Value | 101 | 1 |
| Deals by Molecule Type, Molecular Target and Value | 102 | 2 |
| Table for Licensing Deals Valued Above $300m | 104 | 1 |
| Co-development Deals | 105 | 1 |
| Deals by Region, Year and Value | 105 | 1 |
| Deals by Stage of Development and Value | 106 | 2 |
| Deals by Molecule Type, Molecular Target and Value | 108 | 1 |
| Table for Co-development Deals Valued Above $300m | 109 | 2 |
| Appendix | 111 | 51 |
| References | 111 | 4 |
| Table of Epidemiology Forecast | 115 | 1 |
| Table of All Clinical Stage Pipeline Products | 116 | 41 |
| Abbreviations | 157 | 1 |
| Disease List | 158 | 1 |
| Methodology | 159 | 2 |
| Coverage | 159 | 1 |
| Secondary Research | 159 | 1 |
| Market Size and Revenue Forecasts | 159 | 1 |
| Pipeline Analysis | 160 | 1 |
| Competitive Landscape | 160 | 1 |
| Contact Us | 161 | 1 |
| Disclaimer | 161 | 1 |